Skip to main content

Table 4 Comparison of all lupus nephritis treatments for fertility issues (amenorrhea or ovarian failure)

From: Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis

Treatment Reference OR (95 % CrI) RR (95 % CrI) RD % (95 % Crl)
CYC PRED 3.81 (1.26, 14.31) 2.64 (1.18, 7.51) 0.25 (0.04, 0.47)
MMF   0.48 (0.09, 3.04) 0.52 (0.11, 2.58) −0.07 (−0.23, 0.13)
AZA   2.74 (0.26, 28.27) 2.12 (0.30, 8.18) 0.17 (−0.15, 0.65)
CYC LD   9.06 (0.63, 121.50) 3.79 (0.68, 11.71) 0.45 (−0.06, 0.81)
MMF CYC 0.13 (0.03, 0.41) 0.20 (0.05, 0.56) 0.31 (0.47,0.16)
AZA   0.69 (0.09, 5.08) 0.79 (0.14, 1.95) −0.08 (−0.37, 0.36)
CYC LD   2.23 (0.23, 23.20) 1.46 (0.34, 2.71) 0.19 (−0.27, 0.55)
AZA MMF 5.25 (0.78, 54.39) 3.68 (0.81, 19.08) 0.22 (−0.02, 0.68)
CYC LD   16.35 (1.97, 247.70) 6.49 (1.72, 30.95) 0.50 (0.06, 0.87)
CYC LD AZA 3.20 (0.55, 21.24) 1.69 (0.68, 6.12) 0.22 (−0.11, 0.60)
Random-effects model Residual deviance 15.93 vs. 17 data points
  Deviance information criteria 72.233
Fixed-effects model Residual deviance 16.16 vs. 17 data points
  Deviance information criteria 72.069
  1. Based on eight RCTs with 839 patients: seven two-arm trials and one three-arm trial
  2. Significant odds ratios are in italics
  3. For absolute rates for events used for calculation of risk difference, please see Appendix 6
  4. OR odds ratio, RR relative risk, RD risk difference, CrI credible interval, HD high dose, LD low dose; when not specified, it indicates standard dose, CYC cyclophosphamide, MMF mycophenolate mofetil, CSA cyclosporine, TAC tacrolimus, LEF leflunomide, PRED prednisone, prednisolone or methylprednisolone, AZA azathioprine, RTX rituximab
  5. The odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients